This series brings top tier industry participants to our community to share their experience and discuss topics of interest to entrepreneurs. Speakers include CEOs, management, venture capitalists, angel investors, lawyers and others involved in the Silicon Valley ecosystem. There is an opportunity to meet the speaker and network with other participants at a reception after the talk.
Upcoming Speaker Series
Tuesday, June 6th, 5:30-7:30pm, Mission Bay. Fireside Chat with George Scangos, former CEO Biogen; CEO Vir Biotechnology. George has been named one of the 25 most influential people in biotech, leading Biogen for six years before leaving at the end of 2016. Sales at Biogen more than doubled under his leadership, from $4.7 billion in 2010 to $10.8 billion last year. During his tenure, he effected a turnaround by restructuring the company, divesting its Idec cancer drug division, refocusing research on neurology and hematology and presiding over the rollout of six new drugs including a blockbuster M.S. drug. His next challenge is to build Vir, founded by Bob Nelsen/Arch Ventures, which is taking on infectious diseases with more than $150MM starting commitment from Arch and Gates Foundation. Vir, which has been in stealth mode, seeks to use breakthroughs in immune programming to manipulate pathogen-host interactions. Hear from this biotech icon who has held one of the most important jobs in the industry and is reentering the startup world. Tickets.
Past Speaker Series
May 1, 2017 5:30-7:30pm, Mission Bay. Speaker Series: Building Companies from Exceptional Science, Robert Nelsen. Robert Nelsen, MBA, Cofounder and Managing Director of Arch Venture Partners, is responsible for many of the most exciting investments in life sciences. Recent investments include Denali, GRAIL and Juno. Over a thirty-year career, Nelsen has had two dozen companies go public and was the initial investor on Illumina. Nineteen of his 30 investments have reached valuations exceeding $1 billion. He has been called “the biggest dreamer in biotech investing” and was the top healthcare VC on the Forbes Midas List. Bob is known for playing a significant role in the early sourcing, financing and development of companies. He will share his formula for creating successful ventures. Tickets.
February 7, 2017 5:30-7:30pm, Mission Bay. Raising Big Money to Solve Neurodegeneration, Ryan Watts, CEO and Cofounder, Denali Therapeutics. Denali debuted in 2015 to work in neurodegenerative diseases with a biotech record breaking $217MM Series A investment from top tier venture capitalists. VC’s backed a dream team -- Ryan headed neuroscience at Genentech and the founding group includes Stanford’s new president. Denali has a novel approach to Alzheimer’s and Parkinson’s and the funding to pursue innovation. Ryan will speak about forming the company, how he is putting the funds to work (now including a $130MM Series B) and how he intends to reverse the industry’s long record of failure in Alzheimer's and Parkinson's diseases with an approach that applies the translational rigor seen in oncology. Tickets.
November 15, 2016 5:30-7:30pm, UCSF Mission Bay. Financing Trends in Life Science. Jonathan will provide an overview of the life science venture landscape in biopharma, device and tools/Dx. A nationally prominent analyst and speaker about financing trends, he authors the Bank’s widely read “Healthcare Investments and Exits Report.” Topics will include the current equity financing landscape and Series A investing; analysis of most active venture firms, the crossover phenomenon and what it means; which crossovers are investing and at which stage; what it takes to generate IPO success; stage and indication for merger/acquisition exits and the IPO environment. Tickets.
April 7, 2016 5:30-7:30pm, UCSF Mission Bay. How You Can Tap an Investment from our $950MM Fund. Orbimed is a life science focused venture capital firm that has been investing for the past 20 years and manages $15 billion, Their Fund VI closed with $950 million in December 2015. The new Fund will invest in all stages and sectors of the healthcare industry with a focus on biopharmaceuticals, medical devices, diagnostics and healthcare IT companies located in North America and Europe. Orbimed expects to invest in approximately 30 portfolio companies in amounts generally ranging from $10 million to $75 million. Learn what a top VC looks for in its investments and how you can interest a VC in your startup. Build your network with other entrepreneurs afterwards. Tickets
March 17, 2016 5:30-7:30pm, UCSF Mission Bay. What Big Data Means to Your Healthtech Startup with Atul Butte MD PhD. Atul is a world-renowned expert in medical technology, Big Data guru and an entrepreneur. He will talk about how publicly available biomedical research data can be the basis for your startup. There’s an urgent need to translate genome-era discoveries into clinical usefulness but the difficulties in making bench-to-bedside translations have been well described. The emerging field of translational bioinformatics may help. Atul’s Institute builds and applies computational tools to convert hundreds of trillions of points of molecular, clinical and epidemiological data collected by researchers and clinicians worldwide over the past decade into new diagnostics, therapeutics, and insights into diseases both rare and common. Tickets.
February 3, 2016 5:30-7:30pm, UCSF Mission Bay. The Health 2.0 Revolution with Matt Holt. The Health 2.0 Revolution. Through its conferences and blog, Matthew and Health 2.0 have become primary arbiters of what’s happening in digital health. Hear what’s hot in healthtech and where it’s all going this year, the latest trends, what’s getting funded, what isn’t and what to look out for. Tickets.
September 24 2015 5:30-8:30pm, UCSF Mission Bay. Speaker Series: What Do Investors Want? New Enterprise Associates (NEA) is a top tier venture capital firm that invests in biopharmaceuticals, healthcare services/IT and devices and recently raised a $3 billion fund. Xfund, cofounded by former NEA partner Chung, is a $100 million seed and early stage fund affiliated with Harvard and other universities. Find out what investors are looking for at both stages and whether you’ve got it. Tickets.
April 23, 2015 5:30-7:30pm, UCSF Mission Bay. Speaker Series: Building a Biotech Company from Scratch: Challenges & Successes -- from Startup to Publicly Traded Company. OncoMed is a clinical development-stage company focused on first-in-class monoclonal antibody therapeutics targeting cancer stem cells. The company has formed strategic alliances with Celgene, Bayer and GSK and has raised approximately $622 million through venture capital and a 2013 IPO. John Lewicki, EVP, CSO and Founder of OncoMed, will speak about the company's journey from a 3 person startup to a public company with 110 employees. Tickets.
January 28, 2015 5:30-7:30pm. Speaker Series with Paul Yock: Accountable Innovation: New Strategies for Medtech. Hear about the new reality for medical device entrepreneurship from one of the leading lights of the medtech world. Paul Yock, renowned for creating the groundbreaking Stanford BioDesign program to innovate in medical devices, will speak about the future of medtech. The environment for medtech innovation is shifting dramatically with the combined forces of healthcare reform and globalization of markets. Innovators can take advantage of new realities and opportunities to create value in the healthcare system. It’s no longer sufficient to focus only on clinical need; economics is a major factor. Learn about the new landscape and what it means for device entrepreneurs. Tickets.
September 23, 2014 6:00-8:00pm. Speaker Series: Crossover VCs: from Tech to Healthcare. With Scott Nolan, Partner at Founders Fund; Zal Bilimoria, Partner at Andreessen Horowitz and Euan Thomson Operating Partners at Khosla Ventures. Tech VCs are flush with money and looking at healthcare as an opportunity, especially in the areas that relate to tech: digital health and Big Data. We are bringing in a panel that has crossed over into the healthcare world from a base in technology. Hear them talk about their interests, their view of the sector and what they are looking for in an investment. . Sponsored by WilmerHale Tickets.
July 30, 2014 5:30-7:30pm, Mission Bay. Speaker Series: Steve Blank, Lean LaunchPad Architect. Is Your Venture Idea Viable? Hear Steve Blank, the creator of the Lean LaunchPad technique describe how hundreds of teams at Stanford, Berkeley, UCSF and the NSF have derisked their venture by talking to the market first. Steve is an internationally known serial entrepreneur who has changed the face of entrepreneurship training in the US. UCSF collaborated with him and the NSF's I-Corps to invent the Life Sciences/Healthcare version of the course, now adopted by the NIH. Sponsored by WilmerHale. Tickets.
April 15, 2014 6:00-8:00pm, Parnassus. Speaker Series: Blazing the Precision Medicine Trail: Genomic Health’s Journey with Kim Papovits. Kim Popovits, Chairman of the Board, CEO & President. Genomic Health was in personalized medicine before the term was invented. Started from a business plan written in the year 2000, the company has been a trailblazer in genomic-based diagnostics. Kim will describe the company’s path from its visionary founder’s idea to a public company with a market capitalization of over $800MM. Kim became President and Chief Operating Officer in 2002, joining from Genentech where she served as Senior Vice President, Marketing and Sales. At Genentech, she led the successful commercialization of 14 new therapies, including Herceptin. She will share the story of Genomic Health. Sponsored by WilmerHale. Tickets.
February 26, 2014 5:30-7:30pm, Mission Bay. Speaker Series: Has Pharma Found a New Funding Model for Early Stage Life Science? Darren Carroll, Vice President Corporate Business Development, Eli Lilly, will talk about how Lilly is pioneering a new capital efficient model to develop therapeutics by partnering with venture capital firms and leveraging resources. Rather than build complete companies around a single molecule, Lilly’s VC partners set up virtual structures that can utilize Lilly development and avoid sizable overhead. Darren will talk about this program as well as Lilly Ventures, the company’s corporate venture capital fund, which he oversees. He will give his perspective on investment in early stage life science ventures. Sponsored by WilmerHale. Tickets.
January 16, 2014 6:00-8:00pm, Mission Bay. Speaker Series, State of Life science Industry. Steve Burrill, Founder and CEO of investment firm Burrill & Company, will deliver his respected annual analysis of the life science industry: opportunities, challenges and trends for the next year. Steve’s firm has $1.5 billion in assets under management and includes venture capital/private equity, merchant banking, and media, operating in the US and globally. His view of the industry derives from the scientific and business networks of his team, participation on numerous Advisory Boards; the strategic and financial network of the firm’s limited partners; and the close relationships developed with numerous life science companies and management. Join us to learn what’s in store for the industry and where you should focus to take advantage of the opportunities. Reception sponsored by Goodwin Procter. Tickets.
October 24, 2013 5:30-7:30, Mission Bay. Speaker Series, Winning the Digital Health Space. Join the CEO and Founder of Practice Fusion, Ryan Howard, in conversation with Dirk Lammerts, MD, Managing Director, Digital Health, Burrill & Company. Practice Fusion re-invented the archaic world of Healthcare IT by offering a free, digital platform for Electronic Medical Records (EMRs) to doctors, their practices and their patients, adopted by over 100,000 doctors. The company closed on a $70 MM venture capital round last month. Ryan will discuss starting a Dhealth company, the landscape and business models. Refreshments and networking. Tickets.
June 24, 2013 5:30-7:30pm, Mission Bay. Speaker Series: So you want to start a device company? Learn what’s involved in starting a medical device company, raising funds and strategies to create value from a panel of entrepreneurs and a VC. Veteran serial entrepreneur Rich Lotti, President and CEO, PQ Bypass has started many companies and just raised a funding round. Victor McCray MD, Cofounder and CEO of Ocular Dynamics, did his residency at UCSF, was a Stanford Biodesign Fellow and is a practicing surgeon. Venture capitalist Jay Watkins, Managing Director at De Novo Ventures, cofounded a medical technology startup that was purchased by Eli Lilly and has been investing in device companies for the past decade. These experienced players and a new entrepreneur will inform you about what it takes to get a medical device company off the ground. Tickets.
April 9, 2013 6:00-8:00pm, Mission Bay. Speaker Series: Reflections from All Sides of the Fence. Charles Holmcy, MD, Venture Partner at Third Rock Ventures and Founder, former President and CEO, Portola Pharmaceuticals. Charles will talk about founding Portola, creating value in drug discovery and development, the Third Rock investing model and anything else you ask him about. With 10 years as a UCSF clinical professor and president of a Lederle division, Charles has been in academic medicine, Big Pharma, a biotech startup and venture capital. Third Rock is one of the few remaining early stage life science investors). Charles will share his broad perspective. Tickets.
January 24, 2013 5:30-7:30pm, Mission Bay. Speaker Series: State of the Life Science Industry. UCSF Mission Bay Campus, Byers Auditorium. Steve Burrill, Founder and CEO of investment firm Burrill & Company, will deliver his respected annual analysis of the life science industry: opportunities, challenges and trends for the next year. Steve’s firm has $1.5 billion in assets under management and includes venture capital/private equity, merchant banking, and media, operating in the US and globally. His view of the industry derives from the scientific and business networks of his team, participation on numerous Advisory Boards; the strategic and financial network of the firm’s limited partners; and the close relationships developed with numerous life science companies and management. Join us to learn what’s in store for the industry and where you should focus to take advantage of the opportunities. Tickets.